|Chemical and physical data|
|Molar mass||666.724 g·mol−1|
|3D model (JSmol)|
A combination of the diabetes drug metformin and syrosingopine killed tumor cells in blood samples from leukemia patients, while it did not damage blood cells in samples from healthy patients. The combination of metformin and syrosingopine also reduced or eliminated tumors in mice with malignant liver cancer. The drugs interfere with the cancer cells' glucose (i.e. energy) supply and utilization. Cancer cells have much higher energy requirements than normal cells, making them vulnerable when there is a reduction in the available energy supply. Syrosingopine inhibits the degradation of sugars within the cells.
- "Comparison of syrosingopine and reserpine in the treatment of ambulatory hypertensive patients". The American Journal of the Medical Sciences 245 (3): 304–10. March 1963. doi:10.1097/00000441-196303000-00013. PMID 13977067.
- "Syrosingopine: a new rauwolfia preparation". The New England Journal of Medicine 261 (16): 785–8. October 1959. doi:10.1056/NEJM195910152611603. PMID 13797201.
- "Syrosingopine sensitizes cancer cells to killing by metformin". Science Advances 2 (12): e1601756. December 2016. doi:10.1126/sciadv.1601756. PMID 28028542. Bibcode: 2016SciA....2E1756B. "We report that the anticancer activity of the widely used diabetic drug metformin is strongly potentiated by syrosingopine. Synthetic lethality elicited by combining the two drugs is synergistic and specific to transformed cells.".
- "Treating cancer with drugs for diabetes and hypertension". December 27, 2016. https://www.sciencedaily.com/releases/2016/12/161227083500.htm. "The antihypertensive drug syrosingopine potentiates the anti-cancer efficacy of metformin."
Original source: https://en.wikipedia.org/wiki/Syrosingopine. Read more